Search results

buprenorphine implant (Sixmo)

Substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment.

buprenorphine oral lyophilisate (Espranor)

Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. Treatment with buprenorphine oral lyophilisate is intended for use in adults and adolescents aged 15 years or over who have agreed to be treated for addiction.

buprenorphine (Buvidal)

For the treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over.

buprenorphine/naloxone (Suboxone)

Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Suboxone is indicated in adults and adolescents over 15 years of age who have agreed to be treated for addiction.

buprenorphine/naloxone (Suboxone)

Substitution treatment for opioid drug dependence

buprenorphine and naloxone (Zubsolv)

Substitution treatment for opioid drug dependence.

Buprenorphine (Transtec®) matrix patches

Moderate to severe cancer pain and severe pain that does not respond to non-opioid analgesics

buprenorphine transdermal patches (BuTrans)

Severe opioid responsive pain conditions which are not adequately responding to non-opioid analgesics.

buprenorphine transdermal patch (Butec)

In adults, for the treatment of chronic non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia.

Buprenorphine transdermal patches (BuTrans)

Severe opioid responsive pain conditions which are not adequately responding to non-opioid analgesics

buprenorphine transdermal patch (BuTrans)

Severe osteoarthritis pain in elderly patients, whose pain is not adequately controlled by non opioid analgesics, or for whom other analgesics are not suitable.

buprenorphine transdermal patch (BuTrans)

For the treatment of severe opiod responsive pain conditions which are not adequately responding to non-opiod analgesics

January 2017 decisions news release

The Scottish Medicines Consortium (SMC) has today published advice accepting four new medicines for routine use in NHSScotland.

August 2019 decisions news release

The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday 12 August) published advice accepting four new medicines.

December 2021 decisions news release

SMC accepts six new medicines for use by NHSScotland